Physician profile
Leo Germin
NPI 1013928886
$2,084.00
in general payments reported to CMS, 2019-2025
13 companies · $64.35 in 2025
The $64.35 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $709 · 2021: $514 · 2022: $248 · 2023: $288 · 2024: $260 · 2025: $64.35.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $612.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $612.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $527.91 | 2021-2025 | |
| Nevro Corp. | $289.94 | 2021 | |
| Biogen, INC. | $258.84 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $137.91 | 2019-2024 | |
| Genentech USA, INC. | $127.89 | 2019 | |
| Boston Scientific Corporation | $124.59 | 2022 | |
| Alexion Pharmaceuticals, INC. | $121.83 | 2019 | |
| Genzyme Corporation | $114.94 | 2019 | |
| Emd Serono, INC. | $111.66 | 2022 | |
| Medtronic, INC. | $110.54 | 2023 | Percept PC Brainsense |
| W. L. Gore & Associates, INC. | $91.76 | 2021 | |
| Sunovion Pharmaceuticals INC. | $54.17 | 2019 | |
| Banner Life Sciences, LLC | $12.02 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leo Germin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.